(SILO) Silo Pharma, Inc. Business Model Canvas Research

Silo Pharma, Inc. depends on preclinical service partners such as CROs and specialty labs to run toxicology, pharmacology, and bioanalysis studies, turning early compounds into decision-grade data. In 2025, global CRO revenue was still above $90 billion, showing how much biopharma relies on outsourced study execution.

• Run test and analysis work outside Company
• Speed compound-to-data progress
• Lower fixed lab cost exposure

Silo Pharma, Inc.'s pipeline is still early-stage, so future commercialization will likely rely on outside partners for licensing, co-development, clinical execution, and market access. For biotech, this is common: in 2025, partnering stayed the main route for small developers to move assets from trial data to sales.

• Partner for late-stage trials
• License rights by region
• Share launch and payer access

Silo Pharma, Inc. is advancing CNS programs for PTSD, anxiety, Alzheimer’s disease, and multiple sclerosis, all of which need tight research and clinical validation. The market need is large: about 301 million people live with anxiety disorders worldwide, 55 million with dementia, and nearly 2.9 million with MS.

• High unmet need drives CNS trial focus.
• Validation is slow and data-heavy.

Silo Pharma, Inc. leans on university partners for preclinical and translational research, so collaboration management keeps studies moving and gives access to lab and scientific expertise without adding fixed staff. That matters because a small internal team must coordinate timelines, data sharing, and IP terms across each project.

• Supports research progress
• Gives access to outside expertise
• Extends a lean internal footprint

SPU-16 is a CNS-homing peptide candidate for multiple sclerosis, and it deepens Silo Pharma, Inc.'s focus on neurologic disease. As a pre-revenue biotech, Silo Pharma, Inc. uses this asset to advance targeted CNS delivery, a strategy aimed at improving drug reach in hard-to-treat brain and spinal cord conditions.

• Targets multiple sclerosis in the CNS
• Supports neurologic disease pipeline
• Shows targeted delivery focus

Silo Pharma, Inc. uses university ties to tap research know-how and supporting IP, which matters in early-stage biotech where outside science can cut time and cash burn. In a field where roughly 90% of drug candidates fail before approval, academic IP helps keep the pipeline innovation-led and capital efficient.

• University IP can speed early R&D
• Helps de-risk preclinical work
• Fits an IP-heavy model

Silo Pharma, Inc. centers its pipeline on CNS delivery and activity, spanning psychiatric, neurodegenerative, and demyelinating targets. That focus matters in a market where CNS drug development still has a high failure rate and long timelines, so a clearly defined CNS niche is a key differentiator.

• CNS-first pipeline
• Psychiatric targets
• Neurodegenerative targets
• Demyelinating targets

Silo Pharma pairs conventional drug development with psychedelic-based programs, giving its pipeline two scientific lanes instead of one. The company is advancing two lead clinical-stage programs, SPC-15 and SP-26, which supports an innovation-led story while broadening the evidence base for potential use cases.

• Two lead clinical programs
• Traditional plus psychedelic angle
• Broader pipeline support

As a pre-commercial public company, Silo Pharma, Inc. relies on investor relations to keep shareholders informed through SEC filings, earnings updates, and pipeline news. With no product revenue yet, clear communication helps support financing, visibility, and trust while the Company advances its clinical-stage programs.

• Pre-revenue; no sales yet.
• IR supports capital raises.
• SEC filings keep holders informed.

Silo Pharma, Inc.’s later-stage pipeline will depend on tight ties with clinicians and trial sites, since human studies often need dozens to hundreds of patients per trial and strong site support to hit enrollment. These relationships also help generate the safety and efficacy evidence needed to move from preclinical work into human testing.

• Clinician ties speed patient recruitment
• Site partners improve data quality
• Required for human-trial execution

Scientific outreach is a core channel for Silo Pharma, Inc. in biotech because conference talks, posters, and disclosures put its data in front of researchers and potential partners. It also helps validate the development approach through third-party scientific review, which matters for a small-cap company with limited commercial spend.

• Builds research visibility
• Supports partner interest
• Signals data credibility

If Silo Pharma advances its programs, licensing can become the main way to commercialize them and reach larger biopharma partners. For early-stage drug developers, this is a standard route: in 2024, the global pharma deal market still centered on out-licensing and asset partnerships, with one large deal often worth hundreds of millions in upfront and milestone value.

• Links Silo to bigger biopharma teams
• Fits early-stage drug development
• Can bring upfront and milestone cash

Silo Pharma, Inc.'s SP-26 targets fibromyalgia and chronic pain, reaching a large care base: the CDC says 20.9% of U.S. adults had chronic pain in 2021, and 6.9% had high-impact chronic pain. Pain specialists, rheumatologists, and related care providers are the key future users for this segment.

This is one of Silo Pharma, Inc.'s core therapeutic areas, so uptake depends on clinicians who treat long-term pain and seek non-opioid options.

• SP-26: fibromyalgia and chronic pain
• Key users: pain specialists, care providers
• Large need: 20.9% chronic pain

Silo Pharma, Inc.’s CNS patient segment is people living with Alzheimer’s disease, multiple sclerosis, and psychiatric disorders; they are the end users whose unmet needs shape the pipeline’s value. In the U.S., about 7.2 million people age 65+ lived with Alzheimer’s in 2025, and about 1 million people live with MS, underscoring the size of the need.

• Alzheimer’s: 7.2M U.S. patients
• MS: about 1M U.S. patients
• Psychiatric care drives demand too

Silo Pharma, Inc. faces regulatory costs well before sales, because biotech firms must fund FDA planning, CMC work, and trial-readiness steps before human testing. The FDA’s FY2025 user fee for most IND submissions is $0, but the real cost sits in consulting, documentation, QA, and protocol prep, which can run into hundreds of thousands of dollars per program.

• Pre-IND planning and compliance

• Grows as studies near Phase 1

• Needed before human trials

As a Nasdaq-listed micro-cap, Silo Pharma, Inc. carries fixed public-company costs for SEC reporting, audit, legal, and board governance, while its Sarasota, Florida headquarters adds rent, utilities, and admin support. These overhead items sit inside general and administrative expense and can pressure cash burn when revenue is still limited.

• SEC, audit, and board costs are fixed
• Sarasota HQ adds local operating overhead
• G&A funds the corporate structure

In asset-centric biotech, milestone payments usually arrive after preclinical, clinical, or FDA steps, so Silo Pharma, Inc. can turn partnership progress into cash without direct drug sales. That model fits a company that has been pre-revenue in recent filings, so each signed deal can matter more than current sales volume.

• Paid on development, trial, or regulatory wins
• Fits license-led drug pipelines
• Cash arrives before product sales

Silo Pharma, Inc. has no product revenue yet, so royalties and product sales are only a long-term path if a pipeline asset reaches commercialization. As a developmental-stage company, its current focus stays on R&D, not sales.

• 0 current product revenue
• Future royalties if licensed
• Product sales only after approval